Global Business Travel just had a monster quarter

Global Business Travel shows up and the market notices

Global Business Travel Group didn’t just beat estimates — it basically kicked the door open. The company posted Q1 earnings of 10 cents per share, ahead of the 7-cent consensus, while revenue came in at $840.0 million versus expectations for $816.0 million. The stock did what stocks do when they surprise people in a good way: it launched, climbing 57% to $9.31.

Why investors care

A move like that is the market saying, “Oh, this business might be healthier than we thought.” When a company beats on both earnings and sales, it can suggest demand is holding up, costs are under control, or both — the financial equivalent of finding out your friend is somehow thriving after a rough year.

The rest of Monday’s mover parade

This wasn’t a one-stock show. A bunch of other names joined the green parade:

• Cabaletta Bio priced a $150 million stock offering, and the shares still jumped.
• Celcuity popped after topline Phase 3 data showed it hit its primary endpoint.
• Aura Biosciences also ripped higher after pricing a $260 million equity offering.
• Cullinan Therapeutics climbed after BTIG reiterated a Buy rating and a $38 target.
• Micron got a boost after its CEO talked up AI inference demand for memory.

So yes, Monday had a little something for everyone: earnings, biotech data, analyst love, and the usual capital-raising drama. Wall Street loves a good plot twist.

Big picture: Global Business Travel’s results gave investors a clean, simple story to cheer — beat the numbers, get rewarded, and don’t be surprised when the stock suddenly starts acting like it remembered where the up button is.